Evidence map›Paper›PMID 29534825›Full record

ReviewJournal of the American College of Cardiology2018

Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Stephen J Greene, Muthiah Vaduganathan, Muhammad Shahzeb Khan, George L Bakris, Matthew R Weir, Jonathan H Seltzer, Naveed Sattar, Darren K McGuire, James L Januzzi, Norman Stockbridge and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the American College of Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stephen J GreeneDuke Clinical Research Institute, Durham, North Carolina; Division of Cardiology, Duke University Medical Center, Durham, North Carolina.
Muthiah VaduganathanBrigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts.
Muhammad Shahzeb KhanJohn H. Stroger Jr. Hospital of Cook County, Chicago, Illinois.
George L BakrisASH Comprehensive Hypertension Center, Department of Medicine, University of Chicago, Chicago, Illinois.
Matthew R WeirDivision of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Jonathan H SeltzerACI Clinical, Bala Cynwyd, Pennsylvania.
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Darren K McGuireDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
James L JanuzziDivision of Cardiology, Massachusetts General Hospital, Boston, Massachusetts.
Norman StockbridgeDivision of Cardiovascular and Renal Products, U.S. Food and Drug Administration, Silver Spring, Maryland.
Javed ButlerDepartment of Medicine, University of Mississippi, Jackson, Mississippi. Electronic address: jbutler4@umc.edu.

Funding

Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI HALL, JOHN E · 2016 to 2025
$38.2M
TRAINING PROGRAM IN CARDIOVASCULAR RESEARCHT32HL007604 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARK W FEINBERG · 1985 to 2026
$19.0M
Research Design, Data, and Analytics CoreP30DK092949 · NIDDK · UNIVERSITY OF CHICAGO · PI ELBERT S. HUANG · 2011 to 2026
$10.0M
Postdoctoral Training in Cardiovascular Clinical ResearchT32HL069749 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2003 to 2023
$6.7M
Heart Failure Clinical Trials NetworkU10HL110302 · NHLBI · EMORY UNIVERSITY · PI SMITH, ANDREW · 2012 to 2018
$2.5M
NHLBI NIH HHS T32 HL007604NHLBI NIH HHS T32 HL069749NHLBI NIH HHS U10 HL110302NIDDK NIH HHS P30 DK092949NIGMS NIH HHS U54 GM115428
6 · The paper itself

Abstract

Despite multiple examples of glucose-lowering therapies affecting heart failure (HF) risk, ascertainment of HF data in cardiovascular outcome trials of these medications has not been systematically characterized. In this review, large (n >1,000) published phase III and IV cardiovascular outcome trials evaluating glucose-lowering therapies through June 2017 were identified. Data were abstracted from publications, U.S. Food and Drug Administration advisory committee records, and U.S. Food and Drug Administration labeling documents. Overall, 21 trials including 152,737 patients were evaluated. Rates and definitions of baseline HF and incident HF were inconsistently provided. Baseline ejection fraction data were provided in 3 studies but not specific to patients with HF. No trial reported functional class, ejection fraction, or HF therapy at the time of incident HF diagnosis. HF hospitalization data were available in 15 trials, but only 2 included HF-related events within the primary composite endpoint. This systematic review highlights gaps in HF data capture within cardiovascular outcome trials of glucose-lowering therapies and outlines rationale and strategies for improving HF characterization.

Indexed as

Clinical Trials as TopicDiabetes Mellitus, Type 2Heart FailureHumansIncidencePrevalenceTreatment Outcomeclinical trialdiabetes mellitusheart failuremedicationoutcomes

Identifiers

PMID29534825
PMCPMC5832063

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.